RECTAL ADENOCARCINOMA

This study is testing whether adding two targeted drugs (tucatinib and trastuzumab) to standard chemotherapy before surgery can help shrink tumors in people with a specific type of rectal cancer (HER2-positive). The main goal is to see if this combination leads to a complete disa…

This study is testing if adding the antibiotic metronidazole to standard pre-surgery treatment for rectal cancer can reduce certain harmful bacteria in the gut. Researchers want to see if this change improves how well the cancer responds to treatment. The trial will enroll 60 adu…

This study is testing a new approach for people with stage II-III rectal cancer. After standard chemotherapy and radiation, patients whose cancer appears to be gone will be closely monitored instead of immediately having surgery. The goal is to see if this 'watch and wait' strate…

This study is testing whether a targeted internal radiation treatment can help rectal cancer patients avoid surgery. It is for adults whose cancer did not fully disappear after standard chemotherapy and radiation. The goal is to see if this extra treatment can eliminate the remai…

This study is testing whether adding an immunotherapy drug called TSR-042 before standard chemoradiation and surgery works better for advanced solid tumors with specific genetic features. Researchers want to see if this combination helps eliminate cancer cells more effectively. T…

This early-stage trial is testing whether a short, intense course of radiation followed by several months of chemotherapy can effectively shrink rectal tumors. The main goal is to see if this approach can eliminate the cancer enough that patients can avoid having their rectum sur…

This study is testing if adding two targeted drugs, calderasib and cetuximab, to standard chemotherapy works better for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. It will involve about 477 adults who have not yet received treatment…

This early-stage study is testing whether higher doses of radiation, precisely targeted using real-time MRI guidance, can effectively treat rectal cancer while allowing patients to keep their rectum. The main goal is to find the highest dose that is safe and doesn't cause severe …

This study is testing a personalized treatment plan for people with rectal cancer that hasn't spread. The goal is to avoid removing the rectum when possible by using targeted treatments first, then closely monitoring patients. If surgery is still needed, doctors will use minimall…

This study is testing a new first-line treatment for people with advanced, HER2-positive colorectal cancer that cannot be removed by surgery. It combines three drugs—trastuzumab-deruxtecan, capecitabine, and bevacizumab—to see how well they shrink tumors and control the disease. …

This study is testing a new combination of treatments for people with locally advanced rectal cancer. The goal is to see if adding an immunotherapy drug to a standard mix of radiation, chemotherapy, and a targeted drug can better shrink tumors before surgery. Researchers will com…

This study is testing whether some rectal cancer patients can safely avoid major surgery. It focuses on 200 patients whose tumors disappear completely after initial chemotherapy and radiation. Instead of surgery, patients will enter a closely monitored follow-up program to see if…

This study is testing whether a simple blood test can help doctors decide if rectal cancer patients need major surgery after initial treatment. Researchers will track cancer DNA in the blood of 50 patients with stage 2-3 rectal cancer before, during, and after standard treatment.…

This study aims to understand the long-term bowel problems that can occur after surgery for rectal cancer, a condition known as Low Anterior Resection Syndrome (LARS). Researchers will follow 100 patients for two years after their surgery, using questionnaires to track how their …